Fundraising Fox
Terns Pharmaceuticals
Foster City, US · Founded 2020 · Delaware corporation · 4 known investors
Find your way into Terns Pharmaceuticals
Sign up to see every warm intro you have to Terns Pharmaceuticals
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Terns Pharmaceuticals team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Terns Pharmaceuticals is a biopharmaceutical company developing therapies, including its TERN-701 program. As of May 5, 2026, it operates as a subsidiary of Merck & Co., Inc. (known as MSD outside the US and Canada).
Founders & leadership
MV
Mark Vignola, Ph.D.Executive
SS
Senthil SundaramChief Executive OfficerSenthil Sundaram is a biotechnology executive with approximately two decades of experience in finance, organizational development, clinical development, regulatory affairs, and manufacturing across emerging biopharmaceutical companies focused on liver disease and genetic medicines. He has led fundraising efforts exceeding $1.7 billion and negotiated multiple licensing and acquisition transactions.
WZ
Weidong Zhong, Ph.D.Named on SEC filing
JQ
DF
David FellowsNamed on SEC filing
EW
Elise WangNamed on SEC filing
Board
YS
Yi Shi, Ph.D.Board director
HL
Hongbo Lu, Ph.D.Board director
CG
Carl Gordon, Ph.D.Board director
JK
Jeffrey KindlerBoard director
Investors · 4
Decheng Capitallisted by Decheng CapitalMenlo Park
How we know: Decheng Capital's portfolio page · the VCSheet dataset · Not right? Tell us
Lilly Asia Ventureslisted by Lilly Asia VenturesHong Kongvia Hongbo Lu · inferred
How we know: the VCSheet dataset · Not right? Tell us
Funding
SEC filings, press & company announcements$97.7M disclosed across 1 of 3 rounds · 2020–2025
- Undisclosed amountpublic offeringDec 2025Source ↗
- Undisclosed amountfollow-on equity offeringDec 2025Source ↗
▶$97.7MraisedJan 2021 · 13 investors · PharmaceuticalsRule 506(b)
▶$97.7MraisedJan 2021 · 13 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Weidong Zhong, Ph.D.Executive Officer, Director
- Jill QuigleyDirector
- David FellowsDirector
- Jeffrey KindlerDirector
- Mark Vignola, Ph.D.Executive Officer
- Bryan YoonExecutive Officer
- Yi Shi, Ph.D.Director
- Hongbo Lu, Ph.D.Director
- Carl Gordon, Ph.D.Director
- Elise WangDirector
- Senthil SundaramDirector, Executive Officer
- Offering amount
- $97.7M
- Amount sold
- $97.7M
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
Seeking AlphaSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Companies working in the same space as Terns Pharmaceuticals.
Frequently asked questions
- What does Terns Pharmaceuticals do?
- Terns Pharmaceuticals is a biopharmaceutical company developing therapies, including its TERN-701 program. As of May 5, 2026, it operates as a subsidiary of Merck & Co., Inc. (known as MSD outside the US and Canada).
- Who are Terns Pharmaceuticals's investors?
- Terns Pharmaceuticals's investors include Decheng Capital, LAV, Lilly Asia Ventures, Vivo Capital.
- How much funding has Terns Pharmaceuticals raised?
- Terns Pharmaceuticals has disclosed $97.7M raised across 1 of its 3 known rounds.
- Where is Terns Pharmaceuticals headquartered?
- Terns Pharmaceuticals is headquartered in Foster City, US.